Serial No.: 10/564,010

Confirmation No. 8896

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-91. (Cancelled)

92. (Withdrawn) A compound of formula I:

$$R^{N1} \xrightarrow{N} X \qquad R^3$$

$$R^{1} \times X \qquad R^3$$

$$R^{1} \times X \qquad R^3$$

or a salt, solvate and chemically protected form thereof, wherein:

X is O or NH;

 R^2 and R^3 are independently selected from the group consisting of H, and optionally substituted C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl- C_{1-4} alkyl, and phenyl- C_{1-4} alkyl;

R¹ is an optionally substituted C₉₋₁₄ aryl group or a substituted bi-C₅₋₇ aryl group;

RNI and RN2 are either:

- (i) independently selected from H, R, R', SO₂R, C(=O)R, (CH₂)_nNR^{N3}R^{N4}, where n is from 1 to 4 and R^{N3} and R^{N4} are independently selected from H and R, where R is optionally substituted C₁₋₄ alkyl, and R' is optionally substituted phenyl-C₁₋₄ alkyl, or
- (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C₅₋₇ heterocyclic group;

Attorney's Docket No.: 224823/PO18 US/127425 Serial No.: 10/564,010

Confirmation No. 8896

with the proviso that when R^{N1} , R^{N2} and R^2 are H, R^3 is methyl, and X is NH, then R^1 is not:

- 93. (Withdrawn) The compound according to claim 92, wherein R^{N1} and R^{N2} are both H.
- 94. (Withdrawn) The compound according to claim 92, wherein R² is H.
- 95. (Withdrawn) The compound according to claim 92, wherein R¹ is an optionally substituted biphenyl group.
- 96. (Previously Presented) A compound of formula II:

or a salt, solvate and chemically protected form thereof, wherein:

R⁵ is selected from the group consisting of optionally substituted C₁₋₆alkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, and phenyl-C₁₋₄ alkyl;

R⁴ is an optionally substituted C₉₋₁₄ aryl group;

R^{N5} and R^{N6} are either:

(i) independently selected from H, R, R', SO_2R , C(=O)R, $(CH_2)_nNR^{N7}R^{N8}$, where n is from 1 to 4 and R^{N7} and R^{N8} are independently selected from H and R, where R is optionally substituted C_{1-4} alkyl, and R' is optionally substituted phenyl- C_{1-4} alkyl, or

Attorney's Docket No.: Serial No.: 10/564,010 224823/PO18 US/127425

Confirmation No. 8896

(ii) together with the nitrogen atom to which they are attached, form an optionally substituted C₅₋₇ heterocyclic group.

- 97. (Previously Presented) The compound according to claim 96, wherein at least one of R^{N5} and R^{N6} is H, and the other is selected from H and C(=O)Me.
- 98. (Canceled)
- 99. (Previously Presented) The compound according to claim 96, wherein R⁴ is an optionally substituted 3- or 4-C₅₋₆ aryl-C₅₋₆ aryl group.
- 100. (Withdrawn) A compound of formula Illa or Illb:

or a salt, solvate and chemically protected form thereof,

wherein:

R⁸ is selected from the group consisting of H, and optionally substituted C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, and phenyl-C₁₋₄ alkyl;

 $\ensuremath{R^7}$ is an optionally substituted bi-C_5.7 aryl group;

R^{N9} and R^{N10} are either:

(i) independently selected from H, R, R', SO₂R, C(=O)R, (CH₂)_nNR^{N11}R^{N12}, where n is from 1 to 4 and R^{N11} and R^{N12} are independently selected from H and R, where R is optionally substituted C₁₋₄ alkyl, and R' is optionally substituted phenyl-C₁₋₄ alkyl, or

Attorney's Docket No.: Serial No.: 10/564,010

224823/PO18 US/127425

Confirmation No. 8896

- (ii) together with the nitrogen atom to which they are attached, form an optionally substituted CS-7 heterocyclic group;
 - with the proviso that in formula IIIb, when R^{N9} , R^{N10} and R^8 are H, R^7 is not 4-phenylphenyl.
- 101. (Withdrawn) The compound according to claim 100, wherein R⁸ is selected from H and and optionally substituted C₁₋₆ alkyl.
- 102. (Withdrawn) The compound according to claim 100, wherein R^{N9} and R^{N10} are independently selected from H and R.
- 103. (Withdrawn) The compound according to claim 102, wherein R⁷ is an optionally substituted bi-phenyl group.
- 104. (Withdrawn) A compound of formula IVa or IVb:

or a salt, solvate and chemically protected form thereof, wherein:

- R^{10} is selected from the group consisting of H and optionally substituted C_{1-6} alkyl;
- R⁹ is an optionally substituted C_{9.14} aryl group or an optionally substituted bi-C₅₋₇ aryl group;

R^{N13} and R^{N14} are either:

(i) independently selected from H, R, R', SO₂R, C(=O)R, (CH₂)_nNR^{N15}R^{N16}, where n is from 1 to 4 and R^{N15} and R^{N16} are independently selected from

Attorney's Docket No.: Serial No.: 10/564,010

Confirmation No. 8896

H and R, where R is optionally substituted C_{1-4} alkyl, and R' is optionally substituted phenyl- C_{1-4} alkyl, or

- (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C₅₋₇ heterocyclic group, with the proviso that when R¹⁰, R^{N13} and R^{N14} are H, R⁹ is not an unsubstituted naphthyl group.
- 105. (Withdrawn) The compound according to claim 104, wherein R¹⁰ is selected from H and optionally substituted C_{1.6} alkyl.
- 106. (Withdrawn) The compound according to claim 104, wherein R^{N13} and R^{N14} are independently selected from H and R.
- 107. (Withdrawn) The compound according to claim 104, wherein R⁹ is an optionally substituted bi-phenyl group.
- 108. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to claim 92.
- 109. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to claim 96.
- 110. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to claim 100.
- 111. (Withdrawn) A method of treating a condition which can be alleviated by antagonism of a 5-HT_{2B} receptor, which method comprises administering to a

Attorney's Docket No.: 224823/PO18 US/127425

Serial No.: 10/564,010

patient in need of treatment an effective amount of a compound according to claim 104.

Confirmation No. 8896

- 112. (Withdrawn) The method according to claim 109, wherein the condition which can be alleviated by antagonism of a 5-HT_{2B} receptor is selected from a disorder of the GI tract, migraine, neurogenic pain, pain, anxiety, depression, benign prostatic hyperplasia, sleep disorder, panic disorder, obsessive compulsive disorder, alcoholism, hypertension, anorexia nervosa, priapism asthma, obstructive airway disease, incontinence and bladder dysfunction, disorders of the uterus and pulmonary hypertension.
- 113. (Withdrawn - Currently Amended) The method according to claim 112 115, wherein the disorder of the GI tract is selected from a disorder of gastric motility, dyspepsia, GERD, and tachygastria.
- 114. (Withdrawn - Currently Amended) The method according to claim 112 115 wherein the disorder of the uterus is dysmenorrhoea, pre-term labour, post-partum remodeling, endometriosis and fibrosis.
- (New) The compound of claim 96, wherein one of R^{N5} and R^{N6} is C(=O)Me and 115. the other is H.
- (New)..The compound of claim 96, wherein R⁴ is a C₉₋₁₄ aryl group. 116
- (New) The compound of claim 96, wherein R⁴ is a C₉₋₁₄ aryl group substituted 117. with one or more groups selected from hydroxy, C₁₋₄ alkoxy, cyano, amino, and amido.
- (New) The compound of claim 117, wherein R⁴ is substituted with C₁₋₄ alkoxy. 118.
- (New) The compound of claim 118, wherein R⁴ is substituted with methoxy. 119.